Progyny, Inc.(PGNY)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Progyny, Inc. (PGNY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGNY at 62.7/100 on a 32-signal composite quality model, placing it at rank #691 of 2,961 stocks — the top 25% of the AI-ranked universe. PGNY scores in the top quartile across institutional flow (93.1), earnings quality (87.1), balance sheet strength (86.7). Shareholder dilution risk is elevated at 16.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Progyny, Inc. reports quarterly revenue of $350.5M, net income of $28.1M, an operating margin of 11.4%. Top institutional holders of PGNY by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PGNY trades on the Nasdaq exchange and files with the SEC under CIK 1551306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Progyny, Inc. directly from SEC EDGAR.
AI Quality Score
62.7/100
AI Rank
#691
Revenue
$350.5M
Net Income
$28.1M
Free Cash Flow
$44.2M
Operating Margin
11.4%
PGNY key financials by period
Progyny, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.3B
$58.5M
6.6%
FY 2024
10-K
$1.2B
$54.3M
5.8%
FY 2023
10-K
$1.1B
$62.0M
5.7%
FY 2022
10-K
$786.9M
$30.4M
3.0%
FY 2021
10-K
$500.6M
$65.8M
6.5%
FY 2020
10-K
$344.9M
$46.5M
2.4%
Institutions holding PGNY
Institutional investors reporting a position in Progyny, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-07 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Progyny grew Q2 revenue 5% YoY to $350.5M while gross margin expanded 180bps to 25.5% and net income rose 64% to $28.1M, aided by lower stock-based compensation.
Biggest Revenue Drivers
Fertility benefits services$230.2M+8% YoY
Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025
Increase in clients and covered lives, partially offset by the same large client non-renewal impact
Biggest Revenue Drivers
Total revenue: $350.5M+5% YoY
Fertility benefits services$230.2M+8% YoY
Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025
Increase in clients and covered lives, partially offset by the same large client non-renewal impact
Largest Expense Items
Cost of services$261.2M+3% YoY
Higher medical treatment and pharmacy prescription costs, partially offset by a $3.4M decrease in stock-based compensation and the large client non-renewal impact
General and administrative$31.2M-14% YoY
$5.9M decrease in stock-based compensation as the November 2021 retention grant fully vested in late 2025, partially offset by incremental headcount costs
Sales and marketing$18.1M-2% YoY
$2.6M decrease in stock-based compensation, partially offset by higher other sales and marketing expenses and incremental headcount
Margins: Gross margin rose 180 basis points to 25.5% from 23.7%, driven by ongoing efficiencies in delivery of care management services and lower stock-based compensation expense.
Watch Items from the Filing
No single client accounted for more than 10% of total revenue for the six months ended June 30, 2026, though the filing notes a significant portion of revenue and clients are concentrated in the technology industry.
Revenue growth was tempered by the prior-year loss of a large client whose extended transition-of-care agreement ended June 30, 2025, creating a tougher comp base going forward.
The Consolidated Appropriations Act of 2026 (signed Feb 3, 2026) imposes new PBM disclosure, 100% rebate pass-through, and audit requirements that could affect Progyny Rx's profitability.
Board authorized a new $200M share repurchase program in May 2026 (after completing the $200M November 2025 program); $148.1M of stock was repurchased in the first half of 2026, with $168.5M still available.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
